Canada markets closed

Ultimovacs ASA (ULTIO.OL)

Oslo - Oslo Delayed Price. Currency in NOK
Add to watchlist
110.200.00 (0.00%)
At close: 12:21PM CET
Full screen
Previous Close110.20
Open109.60
Bid104.00 x N/A
Ask105.40 x N/A
Day's Range110.20 - 110.20
52 Week Range110.20 - 110.20
Volume66
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Sidoti Winter Virtual Small Cap Investor Conference

    * Presentation Times and Weblinks Released for Over 70 Presenting Companies * Wednesday and Thursday, January 19th-20th, 2022NEW YORK, NY / ACCESSWIRE / January 18, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Small Cap Virtual Conference taking place Wednesday and Thursday, January 19th-20th, 2022. The links can also be found at www.

  • GlobeNewswire

    Mercer International Inc. to Present at Upcoming 25th Annual CIBC Western Institutional Investor Conference

    NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Mercer International Inc. (Nasdaq: MERC) today announced that David M. Gandossi, President and CEO, will be presenting at the following upcoming conference: 25th Annual CIBC Western Institutional Investor Conference Thursday, January 20th, 2022 Presentation at 2:35 PM PST A copy of the presentation will be posted in the “Investors - News Releases & Presentations” section on the Company’s web site (https://mercerint.com/investors/news-releases-presentat

  • GlobeNewswire

    First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer

    Study assesses impact of UV1 in ovarian cancer maintenance careAddresses unmet medical need among BRCA-negative ovarian cancer patients Enrollment of 184 patients to be coordinated through NSGO-CTU and ENGOT Oslo, 15 December 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced today that the first patient has been enrolled in the DOVACC (Durvalumab Olaparib VACCine) study, a randomized Phase II clinical trial assessing the